Latest Ratios: P/E Ratio -2.6x · EV/EBITDA N/A · ROE -62.7%. (2017–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $555M | $167M | $128M | $314M | $71M | $137M | $104M | $17M | — | — | — |
| Enterprise Value | $398M | $9M | $-6811394 | $106M | $55M | $83M | $40M | $16M | — | — | — |
| P/E Ratio → | -2.56 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 271.48 | — | 284.41 | 814.80 | 120.77 | — | — | — | — |
| P/B Ratio | 1.34 | 0.72 | 0.54 | 1.08 | 1.48 | 1.79 | 1.21 | 11.83 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -14.42 | — | 218.14 | 495.05 | 46.66 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.3% | 100.3% | — | — | — | — | -36.0% | — | — | — | — |
| Operating Margin | 317.1% | 317.1% | -30310.4% | — | -20523.9% | -38053.2% | -3592.0% | — | — | — | — |
| Net Profit Margin | 329.1% | 329.1% | -23956.0% | — | -18919.2% | -40314.1% | -3729.2% | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -62.7% | -62.7% | -42.8% | -45.9% | -76.4% | -83.4% | -73.6% | -211.0% | -24.2% | -60.2% | -43.4% |
| ROA | -57.6% | -57.6% | -40.4% | -43.9% | -68.8% | -76.8% | -68.7% | -183.4% | -23.4% | -49.1% | -28.7% |
| ROIC | -120.3% | -120.3% | -115.8% | -103.0% | -142.8% | -214.7% | -211.7% | — | -138.0% | — | — |
| ROCE | -60.3% | -60.3% | -54.1% | -46.4% | -82.8% | -78.2% | -70.0% | -212.1% | -19.3% | -51.8% | -43.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.68 | -0.57 | -0.71 | -0.34 | -0.70 | -0.74 | -1.07 | -0.80 | -0.98 | -1.48 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -3103.50 | — | — | — | — |
Net cash position: cash ($158M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.52 | 9.52 | 7.75 | 21.65 | 4.09 | 7.38 | 13.57 | 6.24 | 23.32 | 27.38 | 2.88 |
| Quick Ratio | 9.52 | 9.52 | 7.75 | 21.65 | 4.09 | 7.38 | 13.57 | 6.24 | 23.32 | 27.38 | 2.88 |
| Cash Ratio | 8.12 | 8.12 | 6.30 | 20.70 | 2.94 | 6.78 | 13.07 | 5.87 | 23.02 | 27.19 | 2.88 |
| Asset Turnover | — | -0.18 | 0.00 | — | 0.00 | 0.00 | 0.01 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | -41.07 | 4548.30 | — | 4434.99 | 4573.38 | 561.44 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $35M | $20M | $20M | $5M | $4M | $3M | $1M | $365428 | $320151 | $360526 |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HELP stock.
Helus Pharma Inc.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
Helus Pharma Inc.'s return on equity (ROE) is -62.7%. The historical average is -72.3%.
Based on historical data, Helus Pharma Inc. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Helus Pharma Inc. has 100.3% gross margin and 317.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Key Metrics
Top Statement Risk
Clinical trial regulatory failure
Speculative Premium Amidst Clinical Uncertainty
As reported in financial statements, Cybin trades at a price-to-book ratio of 6.52, which appears to reflect investor optimism regarding its deuterated platform rather than current fundamental performance, especially when compared to the broader biotechnology sector's historical valuation ranges for pre-revenue clinical-stage entities.
The elevated P/B ratio suggests that the market is pricing in the potential success of the CYB003 program rather than the company's current book value. Investors should monitor whether this premium holds if clinical timelines extend, as the lack of revenue makes traditional P/E or EV/EBITDA metrics inapplicable for assessing the company's intrinsic value.
Capital Erosion During Development Phase
Based on reported figures, Cybin's ROIC has remained deeply negative, fluctuating between -16.9% and -44.2% over the last ten quarters, which indicates that the company is currently consuming capital to fund R&D rather than generating returns on its invested assets.
The volatility in ROIC appears driven by the lumpy nature of clinical trial expenditures and periodic capital raises. This trend is typical for the industry, yet it underscores the necessity for the company to eventually transition from a capital-consuming R&D entity to a commercial provider to reverse this decay in capital efficiency.
Liquidity Buffers Supporting Clinical Runway
According to recent SEC filings, Cybin's current ratio has shown significant volatility, ranging from 2.89 to 41.70, reflecting the impact of periodic equity-based capital infusions on the company's short-term ability to cover its immediate liabilities during the ongoing Phase 3 trial process.
While the current ratio appears high, it is heavily influenced by cash balances from recent financings rather than operational liquidity. The rapid fluctuation suggests that the company's liquidity position is highly sensitive to the timing of capital raises, warranting close monitoring of the cash burn rate relative to the remaining runway.
Emerging Debt Obligations Impacting Flexibility
As evidenced by the company's balance sheet, Cybin transitioned from a debt-free status to carrying a debt-to-equity ratio of 0.29 by 2026Q1, a shift that warrants further investigation into the cost of capital and potential restrictive covenants attached to these new obligations.
The introduction of debt into a pre-revenue capital structure may indicate a strategic shift toward non-dilutive financing, yet it increases the company's financial risk profile. Investors should assess whether these obligations will require future cash outflows that could compete with the funding needs of critical clinical development programs.
Misapplication of Traditional Profitability Metrics
The most commonly misapplied metric for Cybin is the net margin, which, as noted in historical financial statements, consistently shows negative figures that fail to account for the non-cash nature of share-based compensation and the strategic, long-term investment nature of R&D expenditures.
Using net margin to evaluate Cybin's performance obscures the company's actual operational progress and cash-burn efficiency. Analysts should instead focus on the 'cash-out' rate and clinical milestone achievement, as these metrics provide a more accurate representation of the company's viability than accounting-based profitability ratios.